{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T01:31:58Z","timestamp":1771983118448,"version":"3.50.1"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biotechnol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s12033-023-00994-7","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T11:02:54Z","timestamp":1703070174000},"page":"36-53","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Unveiling the Psychedelic Journey: An Appraisal of Psilocybin as a Profound Antidepressant Therapy"],"prefix":"10.1007","volume":"67","author":[{"given":"Fatima Iftikhar","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Somia","family":"Shehzadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8438-706X","authenticated-orcid":false,"given":"Fatima","family":"Akram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikram ul","family":"Haq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benish","family":"Javed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadeed","family":"Sabir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasha","family":"Kazim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sehrish","family":"Ashfaq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,20]]},"reference":[{"key":"994_CR1","unstructured":"\u201cDepressive Disorder (Depression).\u201d World Health Organization, www.who.int\/news-room\/fact-sheets\/detail\/depression. Accessed 25 Oct 2023. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/depression"},{"key":"994_CR2","doi-asserted-by":"publisher","first-page":"239821281879926","DOI":"10.1177\/2398212818799269","volume":"2","author":"A Kaltenboeck","year":"2018","unstructured":"Kaltenboeck, A., & Harmer, C. (2018). The neuroscience of depressive disorders: A brief review of the past and some considerations about the future. Brain and Neuroscience Advances, 2, 2398212818799269. https:\/\/doi.org\/10.1177\/2398212818799269","journal-title":"Brain and Neuroscience Advances"},{"issue":"5","key":"994_CR3","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2021","unstructured":"Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA psychiatry, 78(5), 481\u2013489. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.3285","journal-title":"JAMA psychiatry"},{"key":"994_CR4","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.neubiorev.2017.08.019","volume":"84","author":"H Akil","year":"2018","unstructured":"Akil, H., Gordon, J., Hen, R., Javitch, J., Mayberg, H., McEwen, B., Meaney, M. J., & Nestler, E. J. (2018). Treatment resistant depression: A multi-scale, systems biology approach. Neuroscience & Biobehavioral Reviews, 84, 272\u2013288. https:\/\/doi.org\/10.1016\/j.neubiorev.2017.08.019","journal-title":"Neuroscience & Biobehavioral Reviews"},{"key":"994_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jad.2013.10.043","volume":"156","author":"RS McIntyre","year":"2014","unstructured":"McIntyre, R. S., Filteau, M. J., Martin, L., Patry, S., Carvalho, A., Cha, D. S., Barakat, M., & Miguelez, M. (2014). Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach. Journal of Affective Disorders, 156, 1\u20137. https:\/\/doi.org\/10.1016\/j.jad.2013.10.043","journal-title":"Journal of Affective Disorders"},{"key":"994_CR6","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5545.117131","volume-title":"Diagnostic and statistical manual of mental disorders: DSM-5","author":"D American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association, D., & Association, A. P. (2013). Diagnostic and statistical manual of mental disorders: DSM-5. American Psychiatric Association. https:\/\/doi.org\/10.4103\/0019-5545.117131"},{"key":"994_CR7","unstructured":"Nolen-Hoeksema, S. (2017). Mood disorders and suicide. Abnormal Psychology, 172\u2013213. ISBN10: 1265316031"},{"issue":"1","key":"994_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.psc.2011.12.001","volume":"35","author":"RV Saveanu","year":"2012","unstructured":"Saveanu, R. V., & Nemeroff, C. B. (2012). Etiology of depression: Genetic and environmental factors. Psychiatric Clinics, 35(1), 51\u201371. https:\/\/doi.org\/10.1016\/j.psc.2011.12.001","journal-title":"Psychiatric Clinics"},{"key":"994_CR9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1146\/annurev.clinpsy.1.102803.143948","volume":"1","author":"SM Southwick","year":"2005","unstructured":"Southwick, S. M., Vythilingam, M., & Charney, D. S. (2005). The psychobiology of depression and resilience to stress: Implications for prevention and treatment. Annual Review of Clinical Psychology, 1, 255\u2013291. https:\/\/doi.org\/10.1146\/annurev.clinpsy.1.102803.143948","journal-title":"Annual Review of Clinical Psychology"},{"issue":"1","key":"994_CR10","doi-asserted-by":"publisher","first-page":"146","DOI":"10.4103\/0973-1229.58825","volume":"8","author":"C Andrade","year":"2010","unstructured":"Andrade, C. (2010). Stahl\u2019s essential psychopharmacology: Neuroscientific basis and practical applications. Mens Sana Monographs, 8(1), 146\u2013150. https:\/\/doi.org\/10.4103\/0973-1229.58825","journal-title":"Mens Sana Monographs"},{"key":"994_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1001\/jama.2009.1943","volume":"303","author":"JC Fournier","year":"2010","unstructured":"Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010). Antidepressant drug effects and depression severity: A patient-level meta-analysis. JAMA, 303, 47\u201353. https:\/\/doi.org\/10.1001\/jama.2009.1943","journal-title":"JAMA"},{"key":"994_CR12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1146\/annurev.clinpsy.2.022305.095301","volume":"4","author":"ME Thase","year":"2008","unstructured":"Thase, M. E., & Denko, T. (2008). Pharmacotherapy of mood disorders. Annual Review of Clinical Psychology, 4, 53\u201391. https:\/\/doi.org\/10.1146\/annurev.clinpsy.2.022305.095301","journal-title":"Annual Review of Clinical Psychology"},{"key":"994_CR13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s12671-014-0379-y","volume":"6","author":"W Van Gordon","year":"2015","unstructured":"Van Gordon, W., Shonin, E., Griffiths, M. D., & Singh, N. N. (2015). There is only one mindfulness: Why science and Buddhism need to work together. Mindfulness, 6, 49\u201356. https:\/\/doi.org\/10.1007\/s12671-014-0379-y","journal-title":"Mindfulness"},{"key":"994_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2016_472","author":"D McKenna","year":"2018","unstructured":"McKenna, D., & Riba, J. (2018). New world tryptamine hallucinogens and the neuroscience of ayahuasca. Behavioral Neurobiology of Psychedelic Drugs. https:\/\/doi.org\/10.1007\/7854_2016_472","journal-title":"Behavioral Neurobiology of Psychedelic Drugs"},{"key":"994_CR15","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1177\/0269881114568039","volume":"29","author":"P-\u00d8 Johansen,","year":"2015","unstructured":"Johansen, P. -\u00d8., & Krebs, T.S. (2015). Psychedelics not linked to mental health problems or suicidal behavior: A population study. Journal of Psychopharmacology, 29, 270\u2013279. https:\/\/doi.org\/10.1177\/0269881114568039","journal-title":"Journal of Psychopharmacology"},{"key":"994_CR16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/s0306-4522(02)00354-8","volume":"2","author":"CD Nichols","year":"2001","unstructured":"Nichols, C. D., & Sanders-Bush, E. (2001). Serotonin receptor signaling and hallucinogenic drug action. The Heffter Review of Psychedelic Research, 2, 73\u201379. https:\/\/doi.org\/10.1016\/s0306-4522(02)00354-8","journal-title":"The Heffter Review of Psychedelic Research"},{"key":"994_CR17","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.3389\/fpsyt.2021.716593","volume":"12","author":"E Argento","year":"2021","unstructured":"Argento, E., Christie, D., Mackay, L., Callon, C., & Walsh, Z. (2021). Psychedelic-assisted psychotherapy after COVID-19: The therapeutic uses of psilocybin and MDMA for pandemic-related mental health problems. Frontiers in Psychiatry, 12, 1528. https:\/\/doi.org\/10.3389\/fpsyt.2021.716593","journal-title":"Frontiers in Psychiatry"},{"issue":"5","key":"994_CR18","doi-asserted-by":"publisher","first-page":"182","DOI":"10.5498\/wjp.v13.i5.182","volume":"13","author":"LN Fonseka","year":"2023","unstructured":"Fonseka, L. N., & Woo, B. K. (2023). Therapeutic role of psilocybin and 3, 4-methylenedioxymethamphetamine in trauma: A literature review. World Journal of Psychiatry, 13(5), 182. https:\/\/doi.org\/10.5498\/wjp.v13.i5.182","journal-title":"World Journal of Psychiatry"},{"key":"994_CR19","doi-asserted-by":"publisher","first-page":"2164957X2210811","DOI":"10.1177\/2164957X221081113","volume":"11","author":"G Vaid","year":"2022","unstructured":"Vaid, G., & Walker, B. (2022). Psychedelic psychotherapy: Building wholeness through connection. Global Advances in Health and Medicine, 11, 2164957X221081113. https:\/\/doi.org\/10.1177\/2164957X221081113","journal-title":"Global Advances in Health and Medicine"},{"key":"994_CR20","doi-asserted-by":"publisher","DOI":"10.1109\/rbme.2021.3134994","author":"DK Tran","year":"2021","unstructured":"Tran, D. K., Phuong, T. N. T., Bui, N.-L., Singh, V., Looi, Q. H., Koh, B., Zaman, U. M. S. B. M., Foo, J. B., Wu, C.-C., & Show, P. L. (2021). Exploring the potential of stem cell-based therapy for aesthetic and plastic surgery. IEEE Reviews in Biomedical Engineering. https:\/\/doi.org\/10.1109\/rbme.2021.3134994","journal-title":"IEEE Reviews in Biomedical Engineering"},{"key":"994_CR21","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.jconrel.2022.02.005","volume":"343","author":"G Bhattacharjee","year":"2022","unstructured":"Bhattacharjee, G., Gohil, N., Khambhati, K., Mani, I., Maurya, R., Karapurkar, J. K., Gohil, J., Chu, D.-T., Vu-Thi, H., & Alzahrani, K. J. (2022). Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications. Journal of Controlled Release, 343, 703\u2013723. https:\/\/doi.org\/10.1016\/j.jconrel.2022.02.005","journal-title":"Journal of Controlled Release"},{"issue":"6","key":"994_CR22","doi-asserted-by":"publisher","first-page":"14681","DOI":"10.1080\/21655979.2022.2100863","volume":"13","author":"OA ElFar","year":"2022","unstructured":"ElFar, O. A., Billa, N., Lim, H. R., Chew, K. W., Cheah, W. Y., Munawaroh, H. S. H., Balakrishnan, D., & Show, P. L. (2022). Advances in delivery methods of Arthrospira platensis (spirulina) for enhanced therapeutic outcomes. Bioengineered, 13(6), 14681\u201314718. https:\/\/doi.org\/10.1080\/21655979.2022.2100863","journal-title":"Bioengineered"},{"key":"994_CR23","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1039\/C8OB02774A","volume":"17","author":"H-C Lin","year":"2019","unstructured":"Lin, H.-C., Hewage, R. TLu., Chooi, Y.-C., & Y-H. (2019). Biosynthesis of bioactive natural products from Basidiomycota. Organic & Biomolecular Chemistry, 17, 1027\u20131036.","journal-title":"Organic & Biomolecular Chemistry"},{"issue":"24","key":"994_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.202200551","volume":"23","author":"T Sch\u00e4fer","year":"2022","unstructured":"Sch\u00e4fer, T., Kramer, K., Werten, S., Rupp, B., & Hoffmeister, D. (2022). Characterization of the gateway decarboxylase for psilocybin biosynthesis. ChemBioChem, 23(24), e202200551. https:\/\/doi.org\/10.1002\/cbic.202200551","journal-title":"ChemBioChem"},{"issue":"12","key":"994_CR25","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.3390\/agronomy12123185","volume":"12","author":"SR Sommano","year":"2022","unstructured":"Sommano, S. R., Suksathan, R., Sombat, T., Seehanam, P., Sirilun, S., Ruksiriwanich, W., Wangtueai, S., & Leksawasdi, N. (2022). Novel perspective of medicinal mushroom cultivations: A review case for \u2018magic\u2019 mushrooms. Agronomy, 12(12), 3185. https:\/\/doi.org\/10.3390\/agronomy12123185","journal-title":"Agronomy"},{"issue":"12","key":"994_CR26","doi-asserted-by":"publisher","first-page":"6950","DOI":"10.1039\/d1cs00065a","volume":"50","author":"CS Jamieson","year":"2021","unstructured":"Jamieson, C. S., Misa, J., Tang, Y., & Billingsley, J. M. (2021). Biosynthesis and synthetic biology of psychoactive natural products. Chemical Society Reviews, 50(12), 6950\u20137008. https:\/\/doi.org\/10.1039\/d1cs00065a","journal-title":"Chemical Society Reviews"},{"issue":"40","key":"994_CR27","doi-asserted-by":"publisher","first-page":"12352","DOI":"10.1002\/anie.201705489","volume":"56","author":"J Fricke","year":"2017","unstructured":"Fricke, J., Blei, F., & Hoffmeister, D. (2017). Enzymatic synthesis of psilocybin. Angewandte Chemie International Edition, 56(40), 12352\u201312355. https:\/\/doi.org\/10.1002\/anie.201705489","journal-title":"Angewandte Chemie International Edition"},{"issue":"40","key":"994_CR28","doi-asserted-by":"publisher","first-page":"10028","DOI":"10.1002\/chem.201801047","volume":"24","author":"F Blei","year":"2018","unstructured":"Blei, F., Baldeweg, F., Fricke, J., & Hoffmeister, D. (2018). Biocatalytic production of psilocybin and derivatives in tryptophan synthase-enhanced reactions. Chemistry: A European Journal, 24(40), 10028\u201310031. https:\/\/doi.org\/10.1002\/chem.201801047","journal-title":"Chemistry: A European Journal"},{"key":"994_CR29","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ymben.2018.05.014","volume":"48","author":"S Hoefgen","year":"2018","unstructured":"Hoefgen, S., Lin, J., Fricke, J., Stroe, M. C., Mattern, D. J., Kufs, J. E., Hortschansky, P., Brakhage, A. A., Hoffmeister, D., & Valiante, V. (2018). Facile assembly and fluorescence-based screening method for heterologous expression of biosynthetic pathways in fungi. Metabolic engineering, 48, 44\u201351. https:\/\/doi.org\/10.1016\/j.ymben.2018.05.014","journal-title":"Metabolic engineering"},{"key":"994_CR30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ymben.2019.09.009","volume":"56","author":"AM Adams","year":"2019","unstructured":"Adams, A. M., Kaplan, N. A., Wei, Z., Brinton, J. D., Monnier, C. S., Enacopol, A. L., Ramelot, T. A., & Jones, J. A. (2019). In vivo production of psilocybin in E. coli. Metabolic engineering, 56, 111\u2013119. https:\/\/doi.org\/10.1016\/j.ymben.2019.09.009","journal-title":"Metabolic engineering"},{"key":"994_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ymben.2019.12.007","volume":"60","author":"N Milne","year":"2020","unstructured":"Milne, N., Thomsen, P., Knudsen, N., Rubaszka, P., Kristensen, M., & Borodina, I. (2020). Metabolic engineering of Saccharomyces cerevisiae for the de novo production of psilocybin and related tryptamine derivatives. Metabolic engineering, 60, 25\u201336. https:\/\/doi.org\/10.1016\/j.ymben.2019.12.007","journal-title":"Metabolic engineering"},{"issue":"2","key":"994_CR32","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264\u2013355. https:\/\/doi.org\/10.1124\/pr.115.011478","journal-title":"Pharmacological Reviews"},{"issue":"10","key":"994_CR33","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41429-020-0311-8","volume":"73","author":"DE Nichols","year":"2020","unstructured":"Nichols, D. E. (2020). Psilocybin: From ancient magic to modern medicine. The Journal of Antibiotics, 73(10), 679\u2013686. https:\/\/doi.org\/10.1038\/s41429-020-0311-8","journal-title":"The Journal of Antibiotics"},{"issue":"3","key":"994_CR34","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/bf02159243","volume":"14","author":"A Hofmann","year":"1958","unstructured":"Hofmann, A., Heim, R., Brack, A., & Kobel, H. (1958). Psilocybin, a psychotropic substance from the Mexican mushroom Psilicybe mexicana Heim. Experientia, 14(3), 107\u2013109. https:\/\/doi.org\/10.1007\/bf02159243","journal-title":"Experientia"},{"issue":"5","key":"994_CR35","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/bf02159243","volume":"177","author":"CM Reiff","year":"2020","unstructured":"Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., & McDonald, W. M. (2020). Psychedelics and psychedelic-assisted psychotherapy. American Journal of Psychiatry, 177(5), 391\u2013410. https:\/\/doi.org\/10.1007\/bf02159243","journal-title":"American Journal of Psychiatry"},{"issue":"37","key":"994_CR36","doi-asserted-by":"publisher","first-page":"8281","DOI":"10.1002\/chem.202000134","volume":"26","author":"J Fricke","year":"2020","unstructured":"Fricke, J., Kargbo, R., Regestein, L., Lenz, C., Peschel, G., Rosenbaum, M. A., Sherwood, A., & Hoffmeister, D. (2020). Scalable hybrid synthetic\/biocatalytic route to psilocybin. Chemistry: A European Journal, 26(37), 8281\u20138285. https:\/\/doi.org\/10.1002\/chem.202000134","journal-title":"Chemistry: A European Journal"},{"issue":"3","key":"994_CR37","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.euroneuro.2013.12.006","volume":"24","author":"F Tyl\u0161","year":"2014","unstructured":"Tyl\u0161, F., P\u00e1len\u00ed\u010dek, T., & Hor\u00e1\u010dek, J. (2014). Psilocybin\u2013summary of knowledge and new perspectives. European Neuropsychopharmacology, 24(3), 342\u2013356. https:\/\/doi.org\/10.1016\/j.euroneuro.2013.12.006","journal-title":"European Neuropsychopharmacology"},{"issue":"5","key":"994_CR38","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/biot.201300445","volume":"9","author":"I Borodina","year":"2014","unstructured":"Borodina, I., & Nielsen, J. (2014). Advances in metabolic engineering of yeast Saccharomyces cerevisiae for production of chemicals. Biotechnology Journal, 9(5), 609\u2013620. https:\/\/doi.org\/10.1002\/biot.201300445","journal-title":"Biotechnology Journal"},{"issue":"4","key":"994_CR39","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/1355621021000005937","volume":"7","author":"T Passie","year":"2002","unstructured":"Passie, T., Seifert, J., Schneider, U., & Emrich, H. M. (2002). The pharmacology of psilocybin. Addiction Biology, 7(4), 357\u2013364. https:\/\/doi.org\/10.1080\/1355621021000005937","journal-title":"Addiction Biology"},{"issue":"3","key":"994_CR40","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.neuropharm.2011.01.017","volume":"61","author":"AL Halberstadt","year":"2011","unstructured":"Halberstadt, A. L., & Geyer, M. A. (2011). Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology, 61(3), 364\u2013381. https:\/\/doi.org\/10.1016\/j.neuropharm.2011.01.017","journal-title":"Neuropharmacology"},{"issue":"16","key":"994_CR41","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","volume":"109","author":"LX Shao","year":"2021","unstructured":"Shao, L. X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021). Psilocybin induces rapid and persistent growth of dendritic spines in the frontal cortex in vivo. Neuron, 109(16), 2535\u201344.e4. https:\/\/doi.org\/10.1016\/j.neuron.2021.06.008","journal-title":"Neuron"},{"key":"994_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2021.06.008","author":"AC Kwan","year":"2022","unstructured":"Kwan, A. C., Olson, D. E., Preller, K. H., & Roth, B. L. (2022). The neural basis of psychedelic action. Nature Neuroscience. https:\/\/doi.org\/10.1016\/j.neuron.2021.06.008","journal-title":"Nature Neuroscience"},{"issue":"17","key":"994_CR43","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","volume":"9","author":"FX Vollenweider","year":"1998","unstructured":"Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F., B\u00e4bler, A., Vogel, H., & Hell, D. (1998). Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport, 9(17), 3897\u20133902. https:\/\/doi.org\/10.1097\/00001756-199812010-00024","journal-title":"NeuroReport"},{"issue":"12","key":"994_CR44","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1038\/s41386-020-0718-8","volume":"45","author":"NL Mason","year":"2020","unstructured":"Mason, N. L., Kuypers, K. P. C., M\u00fcller, F., Reckweg, J., Tse, D. H. Y., Toennes, S. W., Hutten, N. R. P. W., Jansen, J. F. A., Stiers, P., Feilding, A., & Ramaekers, J. G. (2020). Me, myself, bye: Regional alterations in glutamate and the experience of ego dissolution with psilocybin. Neuropsychopharmacology, 45(12), 2003\u20132011. https:\/\/doi.org\/10.1038\/s41386-020-0718-8","journal-title":"Neuropsychopharmacology"},{"key":"994_CR45","volume-title":"Psilocybin mushrooms of the world: An identification guide","author":"P Stamets","year":"2023","unstructured":"Stamets, P. (2023). Psilocybin mushrooms of the world: An identification guide. Ten Speed Press."},{"key":"994_CR46","first-page":"167","volume-title":"Natural sources of drugs of abuse: Magic mushrooms","author":"S Ballesteros","year":"2006","unstructured":"Ballesteros, S., Ramon, M. F., Iturralde, M. J., & Mart\u00ednez-Arrieta, R. (2006). Natural sources of drugs of abuse: Magic mushrooms (pp. 167\u2013186). Nova Science."},{"issue":"1","key":"994_CR47","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1080\/03602532.2016.1278228","volume":"49","author":"RJ Dinis-Oliveira","year":"2017","unstructured":"Dinis-Oliveira, R. J. (2017). Metabolism of psilocybin and psilocin: Clinical and forensic toxicological relevance. Drug Metabolism Reviews, 49(1), 84\u201391. https:\/\/doi.org\/10.1080\/03602532.2016.1278228","journal-title":"Drug Metabolism Reviews"},{"issue":"9","key":"994_CR48","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.3390\/molecules26092451","volume":"26","author":"P Cumming","year":"2021","unstructured":"Cumming, P., Scheidegger, M., Dornbierer, D., Palner, M., Quednow, B. B., & Martin-Soelch, C. (2021). Molecular and functional imaging studies of psychedelic drug action in animals and humans. Molecules, 26(9), 2451. https:\/\/doi.org\/10.3390\/molecules26092451","journal-title":"Molecules"},{"issue":"4","key":"994_CR49","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/ftd.0b013e31828741a5","volume":"35","author":"K Stebelska","year":"2013","unstructured":"Stebelska, K. (2013). Fungal hallucinogens psilocin, ibotenic acid, and muscimol: Analytical methods and biologic activities. Therapeutic Drug Monitoring, 35(4), 420\u2013442. https:\/\/doi.org\/10.1097\/ftd.0b013e31828741a5","journal-title":"Therapeutic Drug Monitoring"},{"key":"994_CR50","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/B978-0-323-85215-9.00022-2","volume-title":"Toxicological risk assessment and multi-system health impacts from exposure","author":"D Calina","year":"2021","unstructured":"Calina, D., Carvalho, F., & Docea, A. O. (2021). Toxicity of psychedelic drugs. Toxicological risk assessment and multi-system health impacts from exposure (pp. 545\u2013556). Elsevier."},{"issue":"2","key":"994_CR51","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/s0731-7085(02)00278-9","volume":"30","author":"F Hasler","year":"2002","unstructured":"Hasler, F., Bourquin, D., Brenneisen, R., & Vollenweider, F. X. (2002). Renal excretion profiles of psilocin following oral administration of psilocybin: A controlled study in man. Journal of Pharmaceutical and Biomedical Analysis, 30(2), 331\u2013339. https:\/\/doi.org\/10.1016\/s0731-7085(02)00278-9","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"issue":"1\u20133","key":"994_CR52","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/s0379-0738(00)00213-9","volume":"113","author":"G Sticht","year":"2000","unstructured":"Sticht, G., & K\u00e4ferstein, H. (2000). Detection of psilocin in body fluids. Forensic Science International, 113(1\u20133), 403\u2013407. https:\/\/doi.org\/10.1016\/s0379-0738(00)00213-9","journal-title":"Forensic Science International"},{"issue":"3","key":"994_CR53","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1520\/JFS15014J","volume":"46","author":"AF Grieshaber","year":"2001","unstructured":"Grieshaber, A. F., Moore, K. A., & Levine, B. (2001). The detection of psilocin in human urine. Journal of Forensic Sciences, 46(3), 627\u2013630.","journal-title":"Journal of Forensic Sciences"},{"key":"994_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.forsciint.2014.01.006","volume":"237","author":"R Martin","year":"2014","unstructured":"Martin, R., Sch\u00fcrenkamp, J., Pfeiffer, H., Lehr, M., & K\u00f6hler, H. (2014). Synthesis, hydrolysis and stability of psilocin glucuronide. Forensic Science International, 237, 1\u20136. https:\/\/doi.org\/10.1016\/j.forsciint.2014.01.006","journal-title":"Forensic Science International"},{"key":"994_CR55","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.21944","author":"S Ziff","year":"2022","unstructured":"Ziff, S., Stern, B., Lewis, G., Majeed, M., & Gorantla, V. R. (2022). Analysis of psilocybin-assisted therapy in medicine: A narrative review. Cureus. https:\/\/doi.org\/10.7759\/cureus.21944","journal-title":"Cureus"},{"issue":"3","key":"994_CR56","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/1556-4029.14268","volume":"65","author":"SP Elliott","year":"2020","unstructured":"Elliott, S. P., Holdbrook, T., & Brandt, S. D. (2020). Prodrugs of new psychoactive substances (NPS): A new challenge. Journal of Forensic Sciences, 65(3), 913\u2013920. https:\/\/doi.org\/10.1111\/1556-4029.14268","journal-title":"Journal of Forensic Sciences"},{"issue":"2","key":"994_CR57","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1124\/dmd.121.000417","volume":"12","author":"MR Meyer","year":"2011","unstructured":"Meyer, M. R., & Maurer, H. H. (2011). Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse. Pharmacogenomics, 12(2), 215\u2013233. https:\/\/doi.org\/10.1124\/dmd.121.000417","journal-title":"Pharmacogenomics"},{"issue":"1","key":"994_CR58","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2492\/INFLAMMREGEN.29.47","volume":"29","author":"Y Matsushima","year":"2009","unstructured":"Matsushima, Y., Eguchi, F., Kikukawa, T., & Matsuda, T. (2009). Historical overview of psychoactive mushrooms. Inflammation and Regeneration, 29(1), 47\u201358. https:\/\/doi.org\/10.2492\/INFLAMMREGEN.29.47","journal-title":"Inflammation and Regeneration"},{"issue":"12","key":"994_CR59","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1177\/0269881116679368","volume":"30","author":"JJ Rucker","year":"2016","unstructured":"Rucker, J. J., Jelen, L. A., Flynn, S., Frowde, K. D., & Young, A. H. (2016). Psychedelics in the treatment of unipolar mood disorders: A systematic review. Journal of Psychopharmacology, 30(12), 1220\u20131229. https:\/\/doi.org\/10.1177\/0269881116679368","journal-title":"Journal of Psychopharmacology"},{"issue":"8","key":"994_CR60","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1177\/02698811221093793","volume":"36","author":"C Jairaj","year":"2022","unstructured":"Jairaj, C., & Rucker, J. J. (2022). Postpartum depression: A role for psychedelics? Journal of Psychopharmacology, 36(8), 920\u2013931. https:\/\/doi.org\/10.1177\/02698811221093793","journal-title":"Journal of Psychopharmacology"},{"key":"994_CR61","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/s2215-0366(16)30065-7","volume":"235","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Curran, H. V., & Nutt, D. J. (2018). Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up. Psychopharmacology, 235, 399\u2013408. https:\/\/doi.org\/10.1016\/s2215-0366(16)30065-7","journal-title":"Psychopharmacology"},{"issue":"15","key":"994_CR62","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/nejmoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus escitalopram for depression. New England Journal of Medicine, 384(15), 1402\u20131411. https:\/\/doi.org\/10.1056\/nejmoa2032994","journal-title":"New England Journal of Medicine"},{"key":"994_CR63","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/jcp.0000000000000436","volume":"37","author":"L Os\u00f3rio Fde","year":"2015","unstructured":"Os\u00f3rio Fde, L., Sanches, R. F., Macedo, L. R., Santos, R. G., Maia-de-Oliveira, J. P., Wichert-Ana, L., Araujo, D. B., Riba, J., Crippa, J. A., & Hallak, J. E. (2015). Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A preliminary report. Brazilian Journal of Psychiatry, 37, 13\u201320. https:\/\/doi.org\/10.1097\/jcp.0000000000000436","journal-title":"Brazilian Journal of Psychiatry"},{"issue":"1","key":"994_CR64","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/jcp.0000000000000436","volume":"36","author":"RF de Sanches","year":"2016","unstructured":"de Sanches, R. F., Dos Lima Os\u00f3rio, F., Santos, R. G., Macedo, L. R., Maia-de-Oliveira, J. P., de Wichert-Ana, L., Araujo, D. B., Riba, J., Crippa, J. A., & Hallak, J. E. (2016). Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A SPECT study. Journal of Clinical Psychopharmacology, 36(1), 77\u201381. https:\/\/doi.org\/10.1097\/jcp.0000000000000436","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"9","key":"994_CR65","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","volume":"330","author":"CL Raison","year":"2023","unstructured":"Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., & Robison, R. (2023). Single-dose psilocybin treatment for major depressive disorder: A randomized clinical trial. JAMA, 330(9), 843\u2013853. https:\/\/doi.org\/10.1001\/jama.2023.14530","journal-title":"JAMA"},{"issue":"2","key":"994_CR66","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/acps.13249","volume":"143","author":"KA Andersen","year":"2021","unstructured":"Andersen, K. A., Carhart-Harris, R., Nutt, D. J., & Erritzoe, D. (2021). Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. Acta Psychiatrica Scandinavica, 143(2), 101\u2013118. https:\/\/doi.org\/10.1111\/acps.13249","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"7","key":"994_CR67","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1177\/0269881118754710","volume":"32","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M. (2018). Psychedelics and the essential importance of context. Journal of Psychopharmacology, 32(7), 725\u2013731. https:\/\/doi.org\/10.1177\/0269881118754710","journal-title":"Journal of Psychopharmacology"},{"key":"994_CR68","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3389\/fphar.2017.00974","volume":"8","author":"L Roseman","year":"2018","unstructured":"Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018). Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Frontiers in Pharmacology, 8, 974. https:\/\/doi.org\/10.3389\/fphar.2017.00974","journal-title":"Frontiers in Pharmacology"},{"key":"994_CR69","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s13311-017-0542-y","volume":"14","author":"MW Johnson","year":"2017","unstructured":"Johnson, M. W., & Griffiths, R. R. (2017). Potential therapeutic effects of psilocybin. Neurotherapeutics, 14, 734\u2013740. https:\/\/doi.org\/10.1007\/s13311-017-0542-y","journal-title":"Neurotherapeutics"},{"issue":"11","key":"994_CR70","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1177\/0269881115609019","volume":"29","author":"FS Barrett","year":"2015","unstructured":"Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2015). Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin. Journal of Psychopharmacology, 29(11), 1182\u20131190. https:\/\/doi.org\/10.1177\/0269881115609019","journal-title":"Journal of Psychopharmacology"},{"key":"994_CR71","doi-asserted-by":"publisher","first-page":"205032451668332","DOI":"10.1177\/2050324516683325","volume":"3","author":"I Hartogsohn","year":"2017","unstructured":"Hartogsohn, I. (2017). Constructing drug effects: A history of set and setting. Drug Science, Policy and Law, 3, 2050324516683325. https:\/\/doi.org\/10.1177\/2050324516683325","journal-title":"Drug Science, Policy and Law"},{"issue":"12","key":"994_CR72","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1177\/0269881116677852","volume":"30","author":"I Hartogsohn","year":"2016","unstructured":"Hartogsohn, I. (2016). Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology. Journal of Psychopharmacology, 30(12), 1259\u20131267. https:\/\/doi.org\/10.1177\/0269881116677852","journal-title":"Journal of Psychopharmacology"},{"issue":"2","key":"994_CR73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030800","volume":"7","author":"E Studerus","year":"2012","unstructured":"Studerus, E., Gamma, A., Kometer, M., & Vollenweider, F. X. (2012). Prediction of psilocybin response in healthy volunteers. PLoS ONE, 7(2), e30800. https:\/\/doi.org\/10.1371\/journal.pone.0030800","journal-title":"PLoS ONE"},{"key":"994_CR74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030800","author":"ECHM Haijen","year":"2018","unstructured":"Haijen, E. C. H. M., Kaelen, M., Roseman, L., Timmermann, C., Kettner, H., Russ, S., Nutt, D., Daws, R. E., Hampshire, A. D. G., Lorenz, R., & Carhart-Harris, R. L. (2018). Predicting responses to psychedelics: A prospective study. Frontiers in pharmacology. https:\/\/doi.org\/10.1371\/journal.pone.0030800","journal-title":"Frontiers in pharmacology"},{"issue":"2","key":"994_CR75","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1021\/acsptsci.0c00192","volume":"4","author":"DE Olson","year":"2020","unstructured":"Olson, D. E. (2020). The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects. ACS Pharmacology & Translational Science, 4(2), 563\u2013567. https:\/\/doi.org\/10.1021\/acsptsci.0c00192","journal-title":"ACS Pharmacology & Translational Science"},{"issue":"10","key":"994_CR76","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/j.cell.2021.03.043","volume":"184","author":"C Dong","year":"2021","unstructured":"Dong, C., Ly, C., Dunlap, L. E., Vargas, M. V., Sun, J., Hwang, I. W., Azinfar, A., Oh, W. C., Wetsel, W. C., Olson, D. E., & Tian, L. (2021). Psychedelic-inspired drug discovery using an engineered biosensor. Cell, 184(10), 2779\u201392.e18. https:\/\/doi.org\/10.1016\/j.cell.2021.03.043","journal-title":"Cell"},{"issue":"7842","key":"994_CR77","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41586-020-3008-z","volume":"589","author":"LP Cameron","year":"2021","unstructured":"Cameron, L. P., Tombari, R. J., Lu, J., Pell, A. J., Hurley, Z. Q., Ehinger, Y., Vargas, M. V., McCarroll, M. N., Taylor, J. C., Myers-Turnbull, D., Liu, T., Yaghoobi, B., Laskowski, L. J., Anderson, E. I., Zhang, G., Viswanathan, J., Brown, B. M., Tjia, M., Dunlap, L. E., \u2026 Olson, D. E. (2021). A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature, 589(7842), 474\u2013479. https:\/\/doi.org\/10.1038\/s41586-020-3008-z","journal-title":"Nature"},{"issue":"9","key":"994_CR78","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1177\/0269881119857204","volume":"33","author":"KP Kuypers","year":"2019","unstructured":"Kuypers, K. P., Ng, L., Erritzoe, D., Knudsen, G. M., Nichols, C. D., Nichols, D. E., Pani, L., Soula, A., & Nutt, D. (2019). Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. Journal of Psychopharmacology, 33(9), 1039\u20131057. https:\/\/doi.org\/10.1177\/0269881119857204","journal-title":"Journal of Psychopharmacology"},{"issue":"6","key":"994_CR79","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1073\/pnas.1119598109","volume":"109","author":"RL Carhart-Harris","year":"2012","unstructured":"Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., Hobden, P., Evans, J., Feilding, A., Wise, R. G., & Nutt, D. J. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences, 109(6), 2138\u20132143. https:\/\/doi.org\/10.1073\/pnas.1119598109","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"8","key":"994_CR80","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.biopsych.2014.04.010","volume":"78","author":"R Kraehenmann","year":"2015","unstructured":"Kraehenmann, R., Preller, K. H., Scheidegger, M., Pokorny, T., Bosch, O. G., Seifritz, E., & Vollenweider, F. X. (2015). Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biological Psychiatry, 78(8), 572\u2013581. https:\/\/doi.org\/10.1016\/j.biopsych.2014.04.010","journal-title":"Biological Psychiatry"},{"issue":"10","key":"994_CR81","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/nrn2345","volume":"9","author":"RJ DeRubeis","year":"2008","unstructured":"DeRubeis, R. J., Siegle, G. J., & Hollon, S. D. (2008). Cognitive therapy versus medication for depression: Treatment outcomes and neural mechanisms. Nature Reviews Neuroscience, 9(10), 788\u2013796. https:\/\/doi.org\/10.1038\/nrn2345","journal-title":"Nature Reviews Neuroscience"},{"issue":"3","key":"994_CR82","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1176\/appi.ajp.159.3.419","volume":"159","author":"GN Pandey","year":"2002","unstructured":"Pandey, G. N., Dwivedi, Y., Rizavi, H. S., Ren, X., Pandey, S. C., Pesold, C., Roberts, R. C., Conley, R. R., & Tamminga, C. A. (2002). Higher expression of serotonin 5-HT2A receptors in the postmortem brains of teenage suicide victims. American Journal of Psychiatry, 159(3), 419\u2013429. https:\/\/doi.org\/10.1176\/appi.ajp.159.3.419","journal-title":"American Journal of Psychiatry"},{"key":"994_CR83","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2174\/1874440001206010055","volume":"6","author":"AA Fingelkurts","year":"2012","unstructured":"Fingelkurts, A. A., Fingelkurts, A. A., Bagnato, S., Boccagni, C., & Galardi, G. (2012). DMN operational synchrony relates to self-consciousness: Evidence from patients in vegetative and minimally conscious states. The Open Neuroimaging Journal, 6, 55. https:\/\/doi.org\/10.2174\/1874440001206010055","journal-title":"The Open Neuroimaging Journal"},{"issue":"10","key":"994_CR84","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3390\/ph14100985","volume":"14","author":"R Zeiss","year":"2021","unstructured":"Zeiss, R., Gahr, M., & Graf, H. (2021). Rediscovering psilocybin as an antidepressive treatment strategy. Pharmaceuticals, 14(10), 985. https:\/\/doi.org\/10.3390\/ph14100985","journal-title":"Pharmaceuticals"},{"issue":"12","key":"994_CR85","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165\u20131180. https:\/\/doi.org\/10.1177\/0269881116675512","journal-title":"Journal of Psychopharmacology"},{"issue":"2","key":"994_CR86","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1177\/0269881119897615","volume":"34","author":"GI Agin-Liebes","year":"2020","unstructured":"Agin-Liebes, G. I., Malone, T., Yalch, M. M., Mennenga, S. E., Pont\u00e9, K. L., Guss, J., Bossis, A. P., Grigsby, J., Fischer, S., & Ross, S. (2020). Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. Journal of Psychopharmacology, 34(2), 155\u2013166. https:\/\/doi.org\/10.1177\/0269881119897615","journal-title":"Journal of Psychopharmacology"},{"issue":"3","key":"994_CR87","doi-asserted-by":"publisher","first-page":"344","DOI":"10.4088\/jcp.07m03780","volume":"70","author":"A Szegedi","year":"2009","unstructured":"Szegedi, A., Jansen, W. T., van Willigenburg, A. P., van der Meulen, E., Stassen, H. H., & Thase, M. E. (2009). Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: A meta-analysis including 6562 patients. Journal of Clinical Psychiatry, 70(3), 344. https:\/\/doi.org\/10.4088\/jcp.07m03780","journal-title":"Journal of Clinical Psychiatry"},{"key":"994_CR88","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/nejmoa2206443","volume":"327","author":"GM Goodwin","year":"2023","unstructured":"Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., P\u00e1len\u00ed\u010dek, T., Redjep, O., Repantis, D., \u2026 Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120\u2013127. https:\/\/doi.org\/10.1056\/nejmoa2206443","journal-title":"Journal of Affective Disorders"},{"key":"994_CR89","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/nmd.0000000000000772","volume":"62","author":"AA Nierenberg","year":"2001","unstructured":"Nierenberg, A. A., Gray, S. M., & Grandin, L. D. (2001). Mood disorders and suicide. Journal of Clinical Psychiatry, 62, 27\u201330. https:\/\/doi.org\/10.1097\/nmd.0000000000000772","journal-title":"Journal of Clinical Psychiatry"},{"key":"994_CR90","volume-title":"Stahl\u2019s essential psychopharmacology: Neuroscientific basis and practical applications","author":"SM Stahl","year":"2013","unstructured":"Stahl, S. M. (2013). Stahl\u2019s essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.","edition":"4"},{"key":"994_CR91","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3389\/fpsyt.2020.00224","volume":"11","author":"K Heuschkel","year":"2020","unstructured":"Heuschkel, K., & Kuypers, K. P. (2020). Depression, mindfulness, and psilocybin: Possible complementary effects of mindfulness meditation and psilocybin in the treatment of depression: A review. Frontiers in Psychiatry, 11, 224. https:\/\/doi.org\/10.3389\/fpsyt.2020.00224","journal-title":"Frontiers in Psychiatry"},{"issue":"10","key":"994_CR92","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/s0006-3223(00)01048-9","volume":"48","author":"MS George","year":"2000","unstructured":"George, M. S., Nahas, Z., Molloy, M., Speer, A. M., Oliver, N. C., Li, X. B., Arana, G. W., Risch, S. C., & Ballenger, J. C. (2000). A controlled trial of daily left prefrontal cortex TMS for treating depression. Biological psychiatry, 48(10), 962\u2013970. https:\/\/doi.org\/10.1016\/s0006-3223(00)01048-9","journal-title":"Biological psychiatry"},{"issue":"1\u20133","key":"994_CR93","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jad.2005.08.013","volume":"89","author":"K Pilkington","year":"2005","unstructured":"Pilkington, K., Kirkwood, G., Rampes, H., & Richardson, J. (2005). Yoga for depression: The research evidence. Journal of Affective Disorders, 89(1\u20133), 13\u201324. https:\/\/doi.org\/10.1016\/j.jad.2005.08.013","journal-title":"Journal of Affective Disorders"},{"key":"994_CR94","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","volume":"142","author":"MW Johnson","year":"2018","unstructured":"Johnson, M. W., Griffiths, R. R., Hendricks, P. S., & Henningfield, J. E. (2018). The abuse potential of medical psilocybin according to the 8 factors of the controlled substances act. Neuropharmacology, 142, 143\u2013166. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.05.012","journal-title":"Neuropharmacology"},{"issue":"10","key":"994_CR95","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.3390\/molecules26102948","volume":"26","author":"H Lowe","year":"2021","unstructured":"Lowe, H., Toyang, N., Steele, B., Valentine, H., Grant, J., Ali, A., Ngwa, W., & Gordon, L. (2021). The therapeutic potential of psilocybin. Molecules, 26(10), 2948. https:\/\/doi.org\/10.3390\/molecules26102948","journal-title":"Molecules"},{"issue":"3","key":"994_CR96","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.yrtph.2011.01.006","volume":"59","author":"J Van Amsterdam","year":"2011","unstructured":"Van Amsterdam, J., van den Opperhuizen, A., & Brink, W. (2011). Harm potential of magic mushroom use: A review. Regulatory Toxicology and Pharmacology, 59(3), 423\u2013429. https:\/\/doi.org\/10.1016\/j.yrtph.2011.01.006","journal-title":"Regulatory Toxicology and Pharmacology"},{"issue":"11","key":"994_CR97","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1111\/j.1445-5994.2012.02955.x","volume":"42","author":"T Lim","year":"2012","unstructured":"Lim, T., Wasywich, C., & Ruygrok, P. (2012). A fatal case of \u201cmagic mushroom\u201d ingestion in a heart transplant recipient. Internal Medicine Journal, 42(11), 1268\u20131269. https:\/\/doi.org\/10.1111\/j.1445-5994.2012.02955.x","journal-title":"Internal Medicine Journal"},{"key":"994_CR98","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5v","volume":"187","author":"RR Griffiths","year":"2006","unstructured":"Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187, 268\u2013283. https:\/\/doi.org\/10.1007\/s00213-006-0457-5v","journal-title":"Psychopharmacology"},{"issue":"3","key":"994_CR99","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.drugpo.2009.08.004","volume":"21","author":"C Wark","year":"2010","unstructured":"Wark, C., & Galliher, J. F. (2010). Timothy Leary, Richard Alpert (Ram Dass) and the changing definition of psilocybin. International Journal of Drug Policy, 21(3), 234\u2013239. https:\/\/doi.org\/10.1016\/j.drugpo.2009.08.004","journal-title":"International Journal of Drug Policy"},{"key":"994_CR100","unstructured":"Abbas, A. I., Carter, A., Jeanne, T., Knox, R., Korthuis, P. T., Hamade, A., Stauffer, C. S., & Uehlinget, J. (2021). Oregon Psilocybin Advisory Board Rapid Evidence Review and Recommendations: Oregon Psilocybin Advisory Board, Salem, OR, USA."},{"issue":"11","key":"994_CR101","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","volume":"28","author":"MW Johnson","year":"2014","unstructured":"Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 28(11), 983\u2013992. https:\/\/doi.org\/10.1177\/0269881114548296","journal-title":"Journal of Psychopharmacology"}],"container-title":["Molecular Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12033-023-00994-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12033-023-00994-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12033-023-00994-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T07:17:07Z","timestamp":1735888627000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12033-023-00994-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,20]]},"references-count":101,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["994"],"URL":"https:\/\/doi.org\/10.1007\/s12033-023-00994-7","relation":{},"ISSN":["1073-6085","1559-0305"],"issn-type":[{"value":"1073-6085","type":"print"},{"value":"1559-0305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,20]]},"assertion":[{"value":"18 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing financial interests. We assure the integrity and quality of our research work. It is also stated that there is no plagiarism in this work and all points taken from other authors are well cited in the text. This study is completely independent and impartial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"N\/A. This research did not involve human participants and\/or animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research Involving Human Participants and\/or Animals"}},{"value":"N\/A. This research did not involve human participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}